SECUAH 2024
dianas | Vol 14 No 1 | marzo 2025 | e202503x002
Expansion of DMSC in High-Glucose Media Enhances Immunosuppression Through Metabolic Reprogramming
Intituto de Investigación Hospital 12 de Octubre
dani.arenas.imas12@h12o.es
X Congreso de Señalización Celular, SECUAH 2024.
XIX Simposio de Dianas Terapéuticas.
17 a 21 de marzo, 2025. Universidad de Alcalá. Alcalá de Henares, Madrid. España.
Keywords: Mesenchymal stem cell therapies; MSC; secretome; Autoimmunity; Connexin 43
Abstract
This study explores the potential of decidua-derived mesenchymal/stromal cells (DMSC) as a promising therapeutic tool for the treatment of autoimmune and inflammatory diseases, aiming to develop a standardized product that optimizes their efficacy. Mesenchymal stem cell (MSC)-based therapies have demonstrated remarkable immunomodulatory effects through the secretion of bioactive factors. However, their clinical effectiveness remains inconsistent, and the molecular mechanisms underlying their action are not yet fully understood.
Citation: Arenas-González D, De-la-Torre-Merino P, Morán-Jiménez MJ, Flores A (2025) Expansion of DMSC in High-Glucose Media Enhances Immunosuppression Through Metabolic Reprogramming. Proceedings of the X Congreso de Señalización Celular, SECUAH 2024. XIX Simposio de Dianas Terapéuticas. 17 a 21 de marzo, 2025. Universidad de Alcalá. Alcalá de Henares, Madrid. España. dianas 14 (1): e202503x002. ISSN 1886-8746 (electronic) journal.dianas.e202503x002. URI http://hdl.handle.net/10017/15181
Copyright: ©2025 Arenas-González D, De-la-Torre-Merino P, Morán-Jiménez MJ, Flores A. Algunos derechos reservados. This is an open-access work licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. http://creativecommons.org/licenses/by-nc-nd/4.0/
